Nanoparticles Mediated Target-specific Drug Delivery in Prostate Cancer: An In-depth Review

Abstract

: Nanotechnology has been extensively exploited for its enormous therapeutics and diagnostics potential in the management of multiple disorders. It employs nanomaterials as drug carriers with enhanced efficacy and limited side effects on normal tissues. A lot of nanomaterials have been studied and produced, imminently reforming the treatment and diagnostics of numerous malignancies including cancer. The purpose of the present study is to explore the role of nanotechnology-based devices/therapies that have a vital function in the therapeutics and diagnostics of cancer with potential impact at three levels: early detection, tumor imaging, and drug delivery methods. Concentrating on cancer, promising nanotechnology-based approaches have been planned to satisfy the need for targeted specificity of traditional agents of chemotherapeutics, in addition to early recognition of malignant and precancerous lesions. Prostate cancer is the fifth utmost well-known cancer worldwide and the second most usually detected cancer in men. Therefore, there is a crucial need to improve therapeutic prospects for the diagnosis and treatment of prostate cancer via exploitation of the potential of nanomaterials for cell-targeted specificity and improved primary diagnosis of precancerous tumours. The present review, therefore, focuses on summarizing all prospective applications of nanotechnology in the prognosis and diagnosis of prostate cancer, which would further help researchers to elucidate a more potent therapeutic approach for the better management of prostate cancer in the days ahead.

Sustained release of alpha‐methylacyl‐CoA racemase (AMACR) antibody‐conjugated and free doxorubicin from silica nanoparticles for prostate cancer cell growth inhibition

“…This can be achieved by the combined use of localized drug delivery methods, and the sustained targeted delivery of cancer drugs with molecular recognition units that can interact directly with receptors that are overexpressed on the surfaces of PC cells. This need has stimulated several studies in which nanotechnology and targeted drugs have been used to develop novel methods for the detection and treatment of PC 13–16 …”

“…This need has stimulated several studies in which nanotechnology and targeted drugs have been used to develop novel methods for the detection and treatment of PC. [13][14][15][16] Mesoporous silica nanoparticles have been widely studied as sustained release cancer drug nanocarriers to inhibit cancer cell growth. [17][18][19][20][21] This is due to their unique properties, such as high total specific surface area, high pore volume, large loading capacity, biocompatibility, and easy surface modification.…”

Three-in-one: exploration of co-encapsulation of cabazitaxel, bicalutamide and chlorin e6 in new mixed cyclodextrin-crosslinked polymers

“…Administration of multiple therapeutic agents remains challenging, however, in this context nanotechnology applied to drug delivery can offer a series of advantages such as the possibility to combine in a unique carrier system more than one therapeutic agent and to increase the bioavailability of the single components. [7][8][9][10] Furthermore, it has been reported that several nanocarriers can afford implementation of classical chemotherapy with other types of treatment like photodynamic therapy (PDT). [11][12][13][14][15] Combination therapy aims at the synergic action of different therapeutics targeting more than one metabolic pathway in order to maximize the impact of the treatment and eventually improve the therapeutic outcome.…”